Dizal Pharmaceutical Hits Day Low of CNY 37.40 Amid Price Pressure

Dizal (Jiangsu) Pharmaceutical Co., Ltd. experienced a significant decline today, with its stock dropping by 4.38% on June 8, 2026. The stock reached an intraday low of CNY 37.40, reflecting ongoing challenges in its financial performance. Over the past week, the stock has seen a steep decline of 22.32%, and its performance over the last month has been even more pronounced, with a decrease of 30.49%. In the context of the broader market, the China Shanghai Composite index has only declined by 1.7% today, highlighting Dizal's underperformance. Year-to-date, the stock has fallen by 34.44%, contrasting sharply with the index's minimal decline of 0.24%. Key financial metrics indicate that Dizal is grappling with low management efficiency, as evidenced by a Return on Capital Employed (ROCE) of 18.72%. Additionally, the company has a high debt-to-equity ratio, which raises concerns about its long-term growth prospects. With a market capitalization of CNY 17,115 million, Dizal continues to face significant challenges in improving its financial standing.